Oral anti-hyperalgesic and anti-inflammatory activity of NK1 receptor antagonists in models of inflammatory hyperalgesia of the guinea-pig

Pain

Volumn 87, Issue 3, 2000, Pages 253-263

  Campbell, Elizabeth A ^a   Gentry, Clive ^a   Patel, Sadhana ^a   Kidd, Bruce ^b   Cruwys, Simon ^b   Fox, Alyson J ^a   Urban, Laszlo ^a  

^a Novatis Inst for Medical Sciences   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Anti hyperalgesia; Gastric erosion; Guinea pig; Hyperalgesia; Inflammation; NK1 receptor antagonists

Indexed keywords

2 NITROPHENYLCARBAMOYLPROLYL 3 (2 NAPHTHYL)ALANYL N BENZYL N METHYLAMIDE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; ACETYLSALICYLIC ACID; CARRAGEENAN; INDOMETACIN; MORPHINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GUINEA PIG; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARRAGEENAN; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; GUINEA PIGS; HUMANS; HYPERALGESIA; INDOLES; MALE; NAPHTHALENES; PIPERIDINES; PROLINE; QUINUCLIDINES; RECEPTORS, NEUROKININ-1;

EID: 0034253822     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(00)00288-8     Document Type: Article

References (47)

1. 1 receptor antagonist SR140333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo- or thermonociception. Naunyn-Schmiedeberg's Arch Pharmacol. 352:1995;201-205.
2. 1 receptors. Br J Pharmacol. 108:1993;223-227.
3. 1-receptors by the use of the non-peptide antagonist, CP-96,345. Br J Pharmacol. 104:1991;292-293.
4. 1 receptor antagonist, (±)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br J Pharmacol. 105:1992;508-510.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
6. 1 receptor activation in gerbils. Eur J Pharmacol. 253:1994;245-252.
7. Caesar M., Seabrook G.R., Kemp J.A. Block of voltage dependent sodium currents by the substance P receptor antagonist (±)-CP-96,345 in neurones cultured from rat cortex. Br J Pharmacol. 109:1993;918-924.
8. Campbell E.A., Gentry C.T., Patel S., Panesar M.S., Walpole C.S.J., Urban L. Selective neurokinin-1 receptor antagonists are anti-hyperalgesic in a model of neuropathic pain in the guinea pig. Neuroscience. 87:1998;527-532.
9. Courteix C., Laverenne J., Eschalier A. RP 67580, a specific tachykinin NK1 receptor antagonist, relieves chronic hyperalgesia in diabetic rats. Eur J Pharmacol. 241:1993;267-270.
10. Cruwys S.C., Garrett N.E., Perkins M.N., Blake D.R., Kidd B.L. The role of bradykinin B1 receptors in the maintenance of intra-articular plasma extravasation in chronic antigen-induced arthritis. Br J Pharmacol. 113:1994;940-944.
11. 1 receptor antagonist. Eur J Pharmacol. 250:1993;403-413.
12. 1 receptor. Neuropeptides. 26:(Suppl):1994;34.
13. Figini M., Javdan P., Cioncolini F., Geppetti P. Involvement of tachykinins in plasma extravasation induced by bradykinin and low pH medium in the guinea-pig conjunctiva. Br J Pharmacol. 115:1995;128-132.
14. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J.-F., Blanchard J.-C., Laduron P.M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA. 88:1991;10208-10212.
15. Gitter B.D., Waters D.C., Bruns R.F., Mason N.R., Nixon J.A., Howbert J.J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 197:1991;237-238.
16. Gitter B.D., Bruns R.F., Howbert J.J., Waters D.C., Threlkeld P.G., Cos L.M., Nixon J.A., Lobb K.L., Mason N.R., Stengel P.W., Cockerham S.L., Silbaigh S.A., Gehlert D.R., Schober D.A., Iyengar S., Calligaro D.O., Regoli D., Hipskind P.A. Pharmacological characterisation of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J Pharmacol Exp Ther. 275:1995;737-744.
17. 1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences. Br J Pharmacol. 110:1993;385-391.
18. Hua X.-Y., Chen P., Polgar E., Nagy I., Marsala M., Phillips E., Wollaston L., Urban L., Yaksh T.L., Webb M. Spinal neurokinin NK1 receptor down-regulation and antinociception: effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy. J Neurochem. 70:1998;688-698.
19. Krause J.E., Blount P., Sachais B.S. Molecular biology of receptors. Buck S.H. The tachykinin receptors. 1994;165-218 Humana Press, Totowa, NJ.
20. + channels. Eur J Pharmacol. 267:1994;113-115.
21. Maggi C.A. Evidence for receptor subtypes/species variants of receptors. Buck S.H. The tachykinin receptors. 1994;395-470 Humana Press, Totowa, NJ.
22. Maggi C.A., Patacchinni R., Rovero P., Giachetti A. Tachykinin receptors and tachykinin receptor antagonists. J Autonom Pharmacol. 13:1993;2393.
23. McCarson K.E., Krause J.E. NK-1 and NK-3 type tachykinin receptor mRNA expression in the rat spinal dorsal horn is increased during adjuvant or formalin-induced nociception. J Neurosci. 14:1994;712-720.
24. McLean S., Ganong A., Seymour P.A., Snider R.M., Desai M.C., Rosen T., Bryce D.K., Longo K.P., Reynolds L.S., Robinson G., Schmidt A.W., Siok C., Heym J. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 267:1993;472-479.
25. 1 receptor. Neuropeptides. 26:(Suppl):1994;35.
26. Nagahisa A., Asai R., Kanai Y., Murase A., Tsuchiya-Nakagaki M., Nakagaki T., Shieh T.-C., Taniguchi K. Non-specific activity of (±)-CP-96,345 in models of pain and inflammation. Br J Pharmacol. 107:1992;273-275.
27. Nagahisa A., Kanai Y., Suga O., Taniguchi K., Tsuchiya M., Lowe J.A., Hess H.-J. Antiinflammatory and analgesic activity of a non-peptide substance P receptor antagonist. Eur J Pharmacol. 217:1992;191-195.
28. Quartara L., Maggi C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides. 32:1998;1-49.
29. Radhakrishnan V., Henry J.L. Novel substance P antagonist CP 96345 blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P. Neurosci Lett. 132:1991;39-43.
30. Rupniak N.M.J., Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharm Sci. 20:1999;485-489.
31. 1 receptor antagonists. Eur J Pharmacol. 265:1994;179-183.
32. 1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol. 110:1993;1607-1613.
33. 1 receptor antagonist, CP-99,994, in conscious gerbils. Br J Pharmacol. 116:1995;1937-1943.
34. Schaible H.-G., Jarrot B., Hope P.J., Duggan A.W. Release of immunoreactive substance P in the spinal cord during development of acute arthritis in the knee joint of the cat: a study with antibody microprobes. Brain Res. 529:1990;214-223.
35. 2+ channels. Eur J Pharmacol. 219:1992;491-492.
36. 2 receptor antagonists: a comparison to other classes of antinociceptive agent. Pain. 61:1992;325-343.
37. 1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse, gerbil. Eur J Pharmacol. 271:1994;481-487.
38. 1) receptor. Science. 251:1991;435.
39. Thompson S.W.N., Dray A., Urban L. Injury-induced plasticity of spinal reflex activity: NK1 neurokinin receptor activation and enhanced A- and C-fibre mediated responses in the rat spinal cord in vitro. J Neurosci. 14:1994;3672-3687.
40. Urban L., Thompson S.W.N., Dray A. Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters. Trends Neurosci. 17:1994;432-438.
41. Vinegar R., Truax J.F., Selph J.L. Quantitative comparison of the analgesic and anti-inflammatory activities of aspirin, phenacetin, and acetaminophen in rodents. Eur J Pharmacol. 37:1976;23-30.
42. Walpole C.W., Brown M., James I., Campbell E.A., Docherty R., Koo S., Urban L. Comparative, general pharmacology of NKT 343, a novel, selective NK-1 receptor antagonist. Br J Pharmacol. 124:1998;83-92.
43. Walsh D.T., Weg V.B., Williams T.J., Nourshargh S. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators. Br J Pharmacol. 114:1995;1343-1350.
44. 1 receptor. Br J Pharmacol. 115:1995;84-94.
45. Woolf C.J., Mannion R.J., Neumann S. Null mutations lacking substance: elucidating pain mechanisms by genetic pharmacology. Neuron. 20:1998;1063-1066.
46. Xu X.-J., Dalsgaard C.-J., Wiesenfeld-Hallin Z. Spinal substance P and N-methyl-D-aspartate receptors are coactivated in the induction of central sensitisation of the nociceptor flexor reflex. Neuroscience. 51:1992;641-648.
47. Yamamoto T., Yaksh T.L. Stereospecific effects of a nonpeptide NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. Life Sci. 49:1991;1955-1963.